Abstract:To address the growing epidemic of liver disease, particularly in pediatric populations, it is crucial to identify modifiable risk factors for the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Per- and polyfluoroalkyl substances (PFAS) are persistent ubiquitous chemicals and have emerged as potential risk factors for liver damage. However, their impact on the etiology and severity of MASLD remains largely unexplored in humans. This study aims to bridge the gap between human and in vitro studies to understand how exposure to perfluoroheptanoic acid (PFHpA), one of the emerging PFAS replacements which accumulates in high concentrations in the liver, contributes to MASLD risk and progression. First, we showed that PFHpA plasma concentrations were significantly associated with increased risk of MASLD in obese adolescents. Further, we examined the impact of PFHpA on hepatic metabolism using 3D human liver spheroids and single-cell transcriptomics to identify major hepatic pathways affected by PFHpA. Next, we integrated the in vivo and in vitro multi-omics datasets with a novel statistical approach which identified signatures of proteins and metabolites associated with MASLD development triggered by PFHpA exposure. In addition to characterizing the contribution of PFHpA to MASLD progression, our study provides a novel strategy to identify individuals at high risk of PFHpA-induced MASLD and develop early intervention strategies. Notably, our analysis revealed that the proteomic signature exhibited a stronger correlation between both PFHpA exposure and MASLD risk compared to the metabolomic signature. While establishing a clear connection between PFHpA exposure and MASLD progression in humans, our study delved into the molecular mechanisms through which PFHpA disrupts liver metabolism. Our in vitro findings revealed that PFHpA primarily impacts lipid metabolism, leading to a notable increase of lipid accumulation in human hepatocytes after PFHpA exposure. Among the pathways involved in lipid metabolism in hepatocytes, regulation of lipid metabolism by PPAR-𝛼 showed a remarkable activation. Moreover, the translational research framework we developed by integrating human and in vitro data provided us biomarkers to identify individuals at a high risk of MASLD due to PFHpA exposure. Our framework can inform policies on PFAS-induced liver disease and identify potential targets for prevention and treatment strategies.

Haloacetamides disinfection by-products, a potential risk factor for nonalcoholic fatty liver disease

Disinfection Byproducts of Haloacetaldehydes Disrupt Hepatic Lipid Metabolism and Induce Lipotoxicity in High-Fat Culture Conditions

Mixed exposure to haloacetaldehyde disinfection by-products exacerbates lipid aggregation in the liver of mice

Associations of Acrylamide with Non-Alcoholic Fatty Liver Disease in American Adults: a Nationwide Cross-Sectional Study

PPARα/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per- and polyfluoroalkyl substances: An integrated approach

Nonalcoholic Fatty Liver Disease Development In Zebrafish Upon Exposure To Bis(2-Ethylhexyl)-2,3,4,5-Tetrabromophthalate, A Novel Brominated Flame Retardant

HADHA alleviates hepatic steatosis and oxidative stress in NAFLD via inactivation of the MKK3/MAPK pathway

Mice in Vivo Toxicity Studies for Monohaloacetamides Emerging Disinfection Byproducts Based on Metabolomic Methods.

Genotoxicity Induced by Low Dose and Mixed Exposure to Haloacetaldehydes, an Emerging Class of Drinking Water Disinfection By-products

Hydrogen-Rich Water (HRW) Reduces Fatty Acid-Induced Lipid Accumulation and Oxidative Stress Damage through Activating AMP-Activated Protein Kinase in HepG2 Cells

Developmental toxicity of disinfection by-product monohaloacetamides in embryo-larval stage of zebrafish

Association of per- and polyfluoroalkyl substances with hepatic steatosis and metabolic dysfunction-associated fatty liver disease among patients with acute coronary syndrome

Cytotoxicity of emerging halophenylacetamide disinfection byproducts in drinking water: Mechanism and prediction

PFHpA alters lipid metabolism and increases the risk of metabolic dysfunction-associated steatotic liver disease in youth-a translational research framework

Chronic exposure to paraben promotes nonalcoholic fatty liver disease by altering lipid metabolism and gut microbiota in mice

In vitro toxicity assessment of haloacetamides via a toxicogenomics assay

Hydrogen-rich Saline Improves Non‑alcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Hepatic PPARα and PPARγ.

Chronic Exposure to Parabens Promotes Non-Alcoholic Fatty Liver Disease in Association with the Changes of the Gut Microbiota and Lipid Metabolism.

New mechanistic insights into halogen-dependent cytotoxic pattern of monohaloacetamide disinfection byproducts

A novel molecular pathway of lipid accumulation in human hepatocytes caused by PFOA and PFOS

Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance